Third Pole Logo

  December 12, 2023   Company Press Releases

– Data from Study Anticipated in Q1 2024 WALTHAM, Mass., December 11, 2023 (GLOBE NEWSWIRE) – Third Pole Therapeutics, Inc., Third Pole Therapeutics, a privately held company developing critical life-sustaining therapies for people living with cardiopulmonary and infectious diseases, today announced that the first patient has been dosed in an early feasibility study (EFS) performed under an Investigational Device Exemption granted …

Third Pole Logo

  December 14, 2022   Company Press Releases

Funding will support the final development phase prior to planned 2023 FDA submission of the company’s “breakthrough” designated eNOcare™ hospital device Waltham, MA –December 14, 2022 – Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator. Bill Athenson, CEO of Third Pole, stated, “We are …

Third Pole Logo

  February 3, 2022   Company Press Releases

eNOfit™, Third Pole’s novel nitric oxide mobile-wearable device designed to provide “on-the-go” treatment for patients suffering from severe COPD and ILD, to enter clinical trials in the second half of this year Funding will support device optimization and clinical trials; Pivotal trial data expected in the second half of 2023 Waltham, MA – February X, 2022 – Third Pole Therapeutics, a privately …

Third Pole Logo

  January 6, 2022   Company Press Releases

WALTHAM, Mass., Jan. 6, 2022 /PRNewswire/ — Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today that it is presenting at the H.C. Wainwright BioConnect 2022 Conference and participating in BIO Partnering at JPM. All events are virtual and scheduled concurrently with the J.P. Morgan 40th Annual Healthcare Conference. Read More >>

  February 24, 2021   Company Press Releases

Waltham, MA – February 24, 2021 – Third Pole, Inc., a privately held company developing and delivering critical life-sustaining cardio-pulmonary therapies, announced today that it has added two seasoned pharmaceutical executives to its Board of Directors, William Heiden, former CEO and Director of AMAG Pharmaceuticals, and Werner Cautreels, Ph.D., former CEO of Selecta Biosciences. Read More >>

Third Pole Logo

  August 21, 2019   Company Press Releases

Newest Patents Cover Nitric Oxide Generation and Wearable Delivery Systems Arlington, MA – August 21, 2019 – Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, announced today that the U.S. Patent and Trademark Office has recently issued U.S. patents covering Third Pole’s innovative general and portable inhaled Nitric Oxide (iNO) delivery systems. >> Read …